Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 8/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | QDPR | P09417 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15006828 | 0.98 | HTR2C (0.55) | SIGMAR1HTR2CHRH3QDPRGRM5 | |
| SCHEMBL12193536 | 0.85 | SIGMAR1 (0.61) | SIGMAR1HTR2CHRH3QDPRGRM5 | |
| Hydrochloric Acid SCHEMBL18113481 | 0.83 | HTR2C (0.62) | SIGMAR1HTR2CQDPRGRM5KDM4E | |
| SCHEMBL12879449 | 0.79 | SIGMAR1 (0.46) | SIGMAR1HTR2CHRH3QDPRGRM5 | |
| SCHEMBL15001446 | 0.79 | HRH3 (0.46) | SIGMAR1HTR2CHRH3QDPRKDM4E | |
| SCHEMBL29138608 | 0.79 | SIGMAR1 (0.55) | SIGMAR1HTR2CHRH3QDPRMAPT | |
| SCHEMBL15001472 | 0.79 | HRH3 (0.46) | SIGMAR1HTR2CHRH3QDPR | |
| SCHEMBL16692796 | 0.79 | HTR2C (0.55) | SIGMAR1HTR2CHRH3QDPRKDM4E | |
| SCHEMBL18059418 | 0.79 | HRH3 (0.46) | SIGMAR1HTR2CHRH3QDPRKDM4E | |
| Hydrochloric Acid SCHEMBL31572375 | 0.77 | HTR2C (0.56) | SIGMAR1HTR2CHRH3QDPRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423436-B1 | PYRIDINYLMETHYL CARBAMIMIDOYLCARBAMATE DERIVATIVES AND THEIR USE AS AOC3 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-10730850-B2 | Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-04 | — | — | US | disclosed |
| US-10336729-B2 | 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-02 | — | — | US | disclosed |
| US-20190084959-A1 | PYRIDINYLMETHYL CARBAMIMIDOYLCARBAMATE DERIVATIVES AND THEIR USE AS AOC3 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-03-21 | — | — | US | disclosed |
| US-20190077790-A1 | 4-CYANO-BENZYL CARBAMIMIDOYLCARBAMATE DERIVATIVES AND THEIR USE AS AOC3 INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2019-03-14 | — | — | US | disclosed |
| EP-2788333-B1 | 1,2,4-TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA | BOEHRINGER INGELHEIM INT (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-8642774-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642774-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20130150341-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150341-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| EP-0925288-B1 | PROCESS OF PRODUCTION OF 4-SUBSTITUTED-3-HALOGENO-1,4-BENZOXAZEPINE DERIVATIVE AND SALTS THEREOF | SUNTORY LTD (JP) | 2002-09-25 | — | — | EP | disclosed |
| CN-1089760-C | Process for production of 4-substituted-3-halogeno-1, 4-benzoxazepine derivative and salts thereof | SUNTORY LTD (JP) | 2002-08-28 | — | — | CN | disclosed |
| EP-0755930-B1 | BENZOXAZEPINE DERIVATIVES, SALTS THEREOF, AND DRUGS CONTAINING THE SAME | SUNTORY LTD (JP) | 2002-07-31 | — | — | EP | disclosed |
| US-6337397-B1 | A BENZOXAZEPINE DERIVATIVE FOR TREATMENT OF ANXIETY NEUROSIS, PHOBIAS, OBSESSIVE-COMPULSIVE DISORDERS, SCHIZOPHRENIA, POST-CARDIAC TRAUMA STRESS DISORDERS, DEPRESSION DISORDERS, PSYCHOSOMATIC DISORDERS AND OTHER PSYCHONEUROTIC DISORDERS, | SUNTORY LIMITED (JP) | 2002-01-08 | — | — | US | disclosed |
| US-6187769-B1 | Benzoxazepine derivatives and their salts and medicaments containing the same | SUNTORY LIMITED (JP) | 2001-02-13 | — | — | US | disclosed |
| US-6114522-A | DEPROTONIZING A BEZOXAZEPINE DERIVATIVE WITH A BASE, REACTING THE DEPROTONIZED PRODUCT WITH A PHOSPHATE HALIDE TO PRODUCE AN INTERMEDIATE, REACTING INTERMEDIATE WITH A COMPLEX OF HALOGEN AND TRIALKYL OR ARYL PHOSPHINE | SUNTORY LIMITED (JP) | 2000-09-05 | — | — | US | disclosed |
| CN-1236363-A | Process for production of 4-substituted-3-halogeno-1, 4-benzoxazepine derivative and salts thereof | SUNTORY LTD (JP) | 1999-11-24 | — | — | CN | disclosed |
| EP-0925288-A1 | PROCESS OF PRODUCTION OF 4-SUBSTITUTED-3-HALOGENO-1,4-BENZOXAZEPINE DERIVATIVE AND SALTS THEREOF | SUNTORY LIMITED (JP) | 1999-06-30 | — | — | EP | disclosed |
| WO-1999003847-A1 | PROCESS OF PRODUCTION OF 4-SUBSTITUTED-3-HALOGENO-1,4-BENZOXAZEPINE DERIVATIVE AND SALTS THEREOF | SUNTORY LIMITED (JP) | 1999-01-28 | — | — | WO | disclosed |
| EP-0755930-A1 | BENZOXAZEPINE DERIVATIVES, SALTS THEREOF, AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150341-A1 | NOVEL COMPOUNDS | GRM5, GRM1, GRIK5 | SIGMAR1 148/4885HTR2C 200/4885HRH3 408/4885 |
| US-20190077790-A1 | 4-CYANO-BENZYL CARBAMIMIDOYLCARBAMATE DERIVATIVES AND THEIR USE AS AOC3 INHIBITORS | AOC3, AOC2, CBR3 | SIGMAR1 2028/4885HTR2C 2986/4885HRH3 3316/4885 |
| US-10336729-B2 | 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | AOC3, AOC2, CBR3 | SIGMAR1 2028/4885HTR2C 2986/4885HRH3 3316/4885 |
| US-10730850-B2 | Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | AOC3, XDH, CYP3A43 | SIGMAR1 3152/4885HTR2C 1340/4885HRH3 2113/4885 |
| US-20190084959-A1 | PYRIDINYLMETHYL CARBAMIMIDOYLCARBAMATE DERIVATIVES AND THEIR USE AS AOC3 INHIBITORS | AOC3, XDH, CYP3A43 | SIGMAR1 3569/4885HTR2C 1735/4885HRH3 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.